The Safety of Radioiodine Therapy for Women of Reproductive Age

Aisyah Elliyanti

doi:10.25077/jom.4.1.1-6.2019

The Safety of Radioiodine Therapy for Women of Reproductive Age

DOI: https://doi.org/10.25077/jom.4.1.1-6.2019

Author(s)

Aisyah Elliyanti (Department of Medical Physics and Radiology, Faculty of Medicine Universitas Andalas)

Abstract

Radioiodine (¹³¹I) is an essential adjuvant treatment after thyroidectomy in patients with differentiated thyroid carcinoma as well as Graves’ disease (hyperthyroidism). Generally ¹³¹I is safe, It has some side effects. Infertility is one an important issues for patients who will consider to receive the therapy, especially for woman in reproductive age. This is reviewed in this paper. Studies reported, in hyperthyroidism and thyroid cancer patients who received ¹³¹I therapy, demonstrated no significant radiation effect, some of patients may have experienced short-term reproductive organs disfunction and changes generally resolve. There is no effect of ¹³¹I to subsequent pregnancy documented.

Full Text:

PDF

References

Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. Eur Thyroid J. Vol. 6, No. 4, 2017, pp.187–196.

Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. Vol. 33.2012, pp.920-80

Brandão Carmen DG, Miranda AE, Corrêa ND, Netto LS, Corbo R, Vaisman M. Radioiodine therapy and subsequent pregnancy. Arq Bras Endocrinol Metab. Vol. 51. 2007. pp. 534-40

Clement SC, Peeters RP, Ronckers CM, Links TP, van den Heuvel-Eibrink MM, Nieveen van Dijkum EJ, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. Intermediate and long-term adverse effect of radioiodine therapy for differentiated thyroid carcinoma- as systematic review. Cancer Treat Rev.Vol.41, 2015.pp. 925-34

Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine 131 therapy for thyroid carcinoma. J Nucl Med. Vol 36. 1995. pp.21-7.

Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. Vol. 95. 2010. Pp. 2227–33

Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D,Hassanzadeh-Rad A,et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear Medicine Communications. Vol. 35, 2014, pp. 808-17

Ko, K. Y., Yen, R. F., Lin, C. L., Cheng, M. F., Huang, W. S., & Kao, C. H. (2016). Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study. Medicine.2016.Vol. 95.e2685.

Mazzaferri EL: Thyroid remnant I ablation for papillary and follicular thyroid carcinoma. Thyroid . Vol 7, 1997. pp.265–271.

Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M, et al. Temporary ovarian failure in thyroid cancer patients after thyroid rem- nant ablation with radioactive iodine. J Clin Endocri- nol Metab. Vol. 69.1989. pp.186–90.

Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNM Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. Journal of Nuclear Medicine. 2012; 53: 1-19

Sioka, Fotopoulos. Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. Fertility and Sterility. Vol. 95.2011. pp.1552-9

Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. Vol. 37, 1996, pp. 606-12.

Vaidya B, Williams GR, Abraham P, Pearce SHS 2008 Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin En- docrinol (Oxf). Vol. 68. 2008. pp. 814–820

Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. Vol. 78. 2002. pp. 92–93

Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. Vol. 1, 1991. pp.129 –135

Zhang Li-Hua, Li Jing-Yan, Tian Qi, Liu Shuang, Zhang Hong, Liu Sheng, et al. Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves’ disease after Iodine-131 treatment, Journal of Radiation Research. Vol. 57, 2016, pp. 702-8.